نتایج جستجو برای: mdr tb

تعداد نتایج: 31722  

2016
Helen R. Stagg Peter J. White Vija Riekstiņa Andra Cīrule Ģirts Šķenders Vaira Leimane Liga Kuksa Gunta Dravniece James Brown Charlotte Jackson

Few studies have examined whether the Xpert MTB/RIF test improves time to treatment initiation for persons with multidrug-resistant tuberculosis (MDR TB). We determined the impact of this test in Latvia, where it was introduced in 2010. After descriptive analyses of pulmonary MDR TB patients in Latvia during 2009-2012, time to treatment initiation was calculated, and univariate and multivariabl...

2010
Bayram Kiran Tulin Cagatay Philip Clark Filiz Kosar Penbe Cagatay Sibel Yurt Faruk Suzergoz Ali Osman Gurol

INTRODUCTION Despite the development and wide implementation of Directly Observed Therapy Strategies (DOTS), multidrug-resistant tuberculosis (MDR-TB) remains a serious global health threat. In this study, the role of host immune response in patients with MDR-TB is investigated and compared with that of patients with smear-positive drug-sensitive tuberculosis (SP-TB). MATERIAL AND METHODS 27 ...

Journal: :The European respiratory journal 2015
Jose A Caminero Anna Scardigli

Multidrug-resistant (MDR) tuberculosis (TB) (resistance to at least isoniazid and rifampicin), with >480000 cases in 2013, 10% of them being affected by extensively drug-resistant (XDR)-TB (MDR-TB with additional resistance to any fluoroquinolone, and to injectable second-line drugs (SLDs) (capreomycin, kanamycin or amikacin)), continues to represent a real threat to TB control [1–4]. In some h...

2015
Feleke Mekonnen Belay Tessema Feleke Moges Aschalew Gelaw Setegn Eshetie Gemechu Kumera

BACKGROUND Multi drug resistant tuberculosis (MDR-TB) is an emerging challenge for TB control programs globally. According to World health organization, 2012 report Ethiopia stands 15(th) out of the 27 high priority countries in the world and 3(rd) in Africa. Updated knowledge of the magnitude of MDR-TB is so substantial to allocate resources, and to address prevention and control measures. The...

2016
Shallo Daba Hamusse Dejene Teshome Mohammed Suaudi Hussen Meaza Demissie Bernt Lindtjørn

BACKGROUND Multidrug-resistant tuberculosis (MDR-TB) drugs which is resistant to the major first-line anti-TB drugs, Isoniazid and Rifampicin, has become a major global challenge in tuberculosis (TB) control programme. However, its burden at community level is not well known. Thus, the aim of study was to assess the prevalence of primary and secondary resistance to any first line anti-TB drugs ...

2017
Setegn Eshetie Mucheye Gizachew Mulat Dagnew Gemechu Kumera Haile Woldie Fekadu Ambaw Belay Tessema Feleke Moges

BACKGROUND Efforts to control the global burden of tuberculosis (TB) have been jeopardized by the rapid evolution of multi-drug resistant Mycobacterium tuberculosis (MTB), which is resistant to at least isoniazid and rifampicin. Previous studies have documented variable prevalences of multidrug-resistant tuberculosis (MDR-TB) and its risk factors in Ethiopia. Therefore, this meta-analysis is ai...

2014
John Z. Metcalfe Salome Makumbirofa Beauty Makamure Charles Sandy Wilbert Bara Stanley Mungofa Philip C. Hopewell Peter Mason

To estimate prevalence of multidrug-resistant tuberculosis (MDR TB) in Harare, Zimbabwe, in 2012, we performed microbiologic testing on acid-fast bacilli smear-positive sputum samples from patients previously treated for TB. Twenty (24%) of 84 specimens were consistent with MDR TB. A national drug-resistance survey is needed to determine MDR TB prevalence in Zimbabwe.

2015
Ntambwe Malangu Omotayo D. Adebanjo

BACKGROUND To date, no study has been found that described the knowledge and practices of healthcare workers surrounding multidrug-resistant tuberculosis (MDR-TB) in Lesotho. AIM AND SETTING: This study was conducted to fill this gap by investigating the knowledge level and practices surrounding MDR-TB amongst healthcare workers at Botsabelo Hospital in Maseru, Lesotho. METHOD This was a cros...

2013
Tae Sun Shim Kyung-Wook Jo

Treatment of multidrug-resistant tuberculosis (MDR-TB) is challenging because of the high toxicity of second-line drugs and the longer treatment duration required compared with drug-susceptible TB. The efficacy of treatment for MDR-TB is poorer than that for drug-susceptible TB. The selection of drugs in MDR-TB is based on previous treatment history, drug susceptibility results, and TB drug res...

2014
Christoph Lange Ibrahim Abubakar Jan-Willem C. Alffenaar Graham Bothamley Jose A. Caminero Anna Cristina C. Carvalho Kwok-Chiu Chang Luigi Codecasa Ana Correia Valeriu Crudu Peter Davies Martin Dedicoat Francis Drobniewski Raquel Duarte Cordula Ehlers Connie Erkens Delia Goletti Gunar Günther Elmira Ibraim Beate Kampmann Liga Kuksa Wiel de Lange Frank van Leth Jan van Lunzen Alberto Matteelli Dick Menzies Ignacio Monedero Elvira Richter Sabine Rüsch-Gerdes Andreas Sandgren Anna Scardigli Alena Skrahina Enrico Tortoli Grigory Volchenkov Dirk Wagner Marieke J. van der Werf Bhanu Williams Wing-Wai Yew Jean-Pierre Zellweger Daniela Maria Cirillo

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment wi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید